Skip to NavigationSkip to content

FDA approves new indication for MSD's Zerbaxa

Published on 05/06/19 at 12:03pm

The FDA has approved US firm Merck’s Zerbaxa (ceftolozane and tazobactam) for adults with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP).

The new indication comes after MSD’s drug was first approved for treating complicated intra-abdominal infections and urinary tract infections by the FDA in 2014.

The drug showed similar efficacy to another antibacterial drug in a clinical trial of 726 patients who had been hospitalised with HABP/VABP.

Elevated liver enzyme levels, renal impairment or failure, and diarrhea were amongst the most commonly reported adverse reactions.

Louis Goss

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches